The second of three hearings on drug pricing planned by the Senate Committee on Health, Education, Labor and Pensions will not happen in July as expected, leaving brand drugmakers with another win on the hotly debated topic.
A spokesman for Senate HELP Committee Chairman Sen. Lamar Alexander confirmed to the Pink Sheet that the senator will delay the hearing, following the politically charged atmosphere of the first hearing on the topic. Democrats used the hearing as a platform to complain about the Senate Republican closed-door process for developing healthcare legislation, and stayed away from in-depth discussions about Rx pricing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?